(Q44168559)

English

Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans

scientific article published on 25 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 November 2017

Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans (English)

1 reference

Europe PubMed Central

30 November 2017

toll-like receptor

0 references

1 reference

based on heuristic

inferred from title

avian influenza

1 reference

based on heuristic

inferred from title

author name string

Wendy Peters

1

1 reference

Europe PubMed Central

30 November 2017

Jennifer R Brandl

2

1 reference

Europe PubMed Central

30 November 2017

Jonathan D Lindbloom

3

1 reference

Europe PubMed Central

30 November 2017

C Josefina Martinez

4

1 reference

Europe PubMed Central

30 November 2017

Ciaran D Scallan

5

1 reference

Europe PubMed Central

30 November 2017

George R Trager

6

1 reference

Europe PubMed Central

30 November 2017

Debora W Tingley

7

1 reference

Europe PubMed Central

30 November 2017

Martin L Kabongo

8

1 reference

Europe PubMed Central

30 November 2017

Sean N Tucker

9

1 reference

Europe PubMed Central

30 November 2017

language of work or name

0 references

publication date

25 January 2013

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

31

1 reference

Europe PubMed Central

30 November 2017

13

1 reference

Europe PubMed Central

30 November 2017

1752-1758

1 reference

Europe PubMed Central

30 November 2017

Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Detecting human-to-human transmission of avian influenza A (H5N1).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Pandemic (avian) influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Airborne transmission of influenza A/H5N1 virus between ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Oral adenoviral-based vaccines: historical perspective and future opportunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Phenotypic Changes in Influenza‐Specific CD8+T Cells after Immunization of Children and Adults with Influenza Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.023

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.01.023

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44168559&oldid=2108229407"